Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
The serine proteinase urokinase-type plasminogen activator (uPA) is widely recognized as a potential target for anticancer therapy. Its association with cell surfaces through the uPA receptor (uPAR) is central to its function and plays an important role in cancer invasion and metastasis. In the current study, we used systematic evolution of ligands by exponential enrichment (SELEX) to select serum-stable 2'-fluoro-pyrimidine-modified RNA aptamers specifically targeting human uPA and blocking the interaction to its receptor at low nanomolar concentrations. In agreement with the inhibitory function of the aptamers, binding was found to be dependent on the presence of the growth factor domain of uPA, which mediates uPAR binding. One of the most potent uPA aptamers, upanap-12, was analyzed in more detail and could be reduced significantly in size without severe loss of its inhibitory activity. Finally, we show that the uPA-scavenging effect of the aptamers can reduce uPAR-dependent endocytosis of the uPA-PAI-1 complex and cell-surface associated plasminogen activation in cell culture experiments. uPA-scavenging 2'-fluoro-pyrimidine-modified RNA aptamers represent a novel promising principle for interfering with the pathological functions of the uPA system.
Dupont
Daniel Miotto
DM
Department of Molecular Biology, University of Aarhus, DK-8000 Aarhus C, Denmark. dmd@mb.au.dk
Madsen
Jeppe Buur
JB
Hartmann
Roland Karl
RK
Tavitian
Bertrand
B
Ducongé
Frédéric
F
Kjems
Jørgen
J
Andreasen
Peter André
PA
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology; D052157:Aptamers, Nucleotide / Q000138:chemical synthesis / Q000494:pharmacology*; D001483:Base Sequence; D004354:Drug Screening Assays, Antitumor; D004355:Drug Stability; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D017434:Protein Structure, Tertiary; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism*; D044967:Serum / Q000378:metabolism; D013379:Substrate Specificity; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D052157:Aptamers, Nucleotide; D046912:Multiprotein Complexes; D017395:Plasminogen Activator Inhibitor 1; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator